Mubadala co-invests in UCB’s pharma carve-out business in China

Mubadala invests in UCB
Image Via: Mubadala | Cropped by GBN
By Arya M Nair, Official Reporter
  • Follow author on

Mubadala Investment Company (Mubadala), the Abu Dhabi-based global investment company in partnership with CBC Group, Asia’s largest healthcare-dedicated asset management group, has acquired 100 percent ownership in the carve-out of UCB Pharma’s mature business in China.

UCB, a global biopharmaceutical company headquartered in Belgium, occupies a market-leading position in the strong and expanding immunology, neurology and rare disease market in China, and is strategically poised for growth in its Central Nervous System (CNS) originator drug portfolio. 

The scope of this acquisition includes UCB’s neurology portfolio (Keppra, Vimpat, Neupro) and allergy portfolio (Zyrtec, Xyzal) in Mainland China, as well as UCB’s Zhuhai manufacturing site. In 2023, the combined net sales for these medicines in China were 131 million euros ($146 million). The transaction remains subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions, and is expected to close in Q4 2024.

This investment aligns with Mubadala’s vision to expand its footprint across Asia through selective investment across diverse sectors with strong growth potential. Healthcare, and specifically pharma carve-outs, are at the forefront of this investment strategy. Additionally, the strategic collaboration with CBC Group, following the Hasten Biopharma acquisition, underscores Mubadala’s ongoing commitment to establishing dedicated platforms to target and serve unmet needs in China and the broader Asia healthcare markets.

Mohamed Albadr_Mubadala acquires UCB Group
Mohamed Albadr
Head of China
Mubadala

“We are thrilled to partner with CBC Group to support the next phase of UCB’s platform as it scales to a leading entity in China and delivers transformative medicines to the markets. The company’s dedication to clinical excellence and innovation aligns with our commitment to enhancing access to care and growth in the healthcare system.”

“CNS is a large and growing therapeutic area in China that has an urgent clinical need. We look forward to building out a broader CNS-focused platform to benefit the Chinese market,” said Mina Hamoodi, Head of Healthcare at Mubadala.

“In the short term, UCB is exploring the launch of novel medicines in immunology, neurology, and rare diseases in China. Our dedication to serving patients with unmet needs in China remains steadfast. Building on our 28-year presence in the country, we are committed to driving patient outcomes through continued collaboration with local partners and fostering innovation. We are convinced that Mubadala and CBC Group are the ideal partners to advance the medicine portfolio and continue to improve the lives of people living with neurology and allergy diseases in mainland China,” stated Jean-Christophe Tellier, CEO at UCB.

Important | RAKBANK partners with Bitpanda to introduce digital assets